Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

In Vitro Activity of Doripenem against Pseudomonas aeruginosa and Burkholderia cepacia Isolates from both Cystic Fibrosis and Non-Cystic Fibrosis Patients

M. M. Traczewski, S. D. Brown
M. M. Traczewski
The Clinical Microbiology Institute, Inc., Wilsonville, Oregon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mtrac@clinmicroinst.com
S. D. Brown
The Clinical Microbiology Institute, Inc., Wilsonville, Oregon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.50.2.819-821.2006
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

  • TABLE 1.

    Percent susceptible, intermediate, and resistant (CLSI breakpoints) for doripenem versus P. aeruginosa and B. cepaciaa

    OrganismAntimicrobialMIC50MIC90MinimumMaximumGeometric meanMode% S% I% R
    All strains (n = 194)Doripenem0.2580.252560.590.25NANANA
    Imipenem1160.252561.37183.004.6012.40
    Levofloxacin180.251281.430.569.1010.8020.10
    Piperacillin81280.25>5129.434SSSSSS
    Ceftazidime2160.25>5122.98288.703.607.70
    Aztreonam8640.25>5127.19866.012.4021.60
    Tobramycin1640.25>5121.780.578.901.0020.10
    Cefepime4320.252564.1278.909.8011.30
    B. cepacia (n = 34)
    Doripenem280.251282.358NANANA
    Imipenem4160.251283.691650.0020.6029.40
    Levofloxacin180.2581.20.2576.5011.8011.80
    Piperacillin321282>51219.22241.2038.2020.60
    Ceftazidime4160.25>5122.83482.4014.702.90
    Aztreonam322560.2551221.726429.4014.7055.90
    Tobramycin641280.2525618.456423.500.0076.50
    Cefepime161280.252568.680.2547.1014.7038.20
    P. aeruginosa (CF isolates; n = 82)
    Doripenem0.2520.252560.520.25NANANA
    Imipenem1160.252561.28186.601.2012.20
    Levofloxacin1160.251281.750.563.4011.0025.60
    Piperacillin82560.25>51210.85486.60NA13.40
    Ceftazidime2320.252563.47284.102.4013.40
    Aztreonam8640.25>5127.8863.4014.6022.00
    Tobramycin0.580.255121.040.589.002.408.50
    Cefepime2160.25643.52284.107.308.50
    P. aeruginosa (non-CF isolates; n = 78)
    Doripenem0.2510.25160.360.25NANANA
    Imipenem120.25320.95193.601.305.10
    Levofloxacin180.25641.250.571.8010.3017.90
    Piperacillin8160.255125.97496.20NA3.80
    Ceftazidime280.25642.61296.200.003.80
    Aztreonam8160.25644.07884.609.006.40
    Tobramycin120.25>5120.970.592.300.007.70
    Cefepime2160.25323.47287.2010.302.60
    • ↵ a Abbreviations: S, susceptible; I, intermediate; R, resistant; NA, not applicable (no approved ranges); SS, species specific. MIC50, MIC90, minimum, maximum, geometric mean, and mode are all in micrograms per milliliter.

  • TABLE 2.

    Doripenem versus imipenem-resistant and -intermediate P. aeruginosa isolatesa

    Strain no.Isolate typeDoripenem MICImipenem MIC, I or R
    N1873CF isolate416R
    N2408CF isolate216R
    N3794CF isolate416R
    N4082CF isolate216R
    N6687CF isolate116R
    N7086Non-CF isolate116R
    N7087Non-CF isolate216R
    N4972CF isolate28I
    N7982Non-CF isolate48I
    N3791CF isolate1664R
    N4077CF isolate816R
    N4079CF isolate256256R
    N5395CF isolate1616R
    N6693CF isolate1616R
    N7093Non-CF isolate1632R
    N7095Non-CF isolate1616R
    • ↵ a MICs are in micrograms per milliliter. I, intermediate; R, resistant.

PreviousNext
Back to top
Download PDF
Citation Tools
In Vitro Activity of Doripenem against Pseudomonas aeruginosa and Burkholderia cepacia Isolates from both Cystic Fibrosis and Non-Cystic Fibrosis Patients
M. M. Traczewski, S. D. Brown
Antimicrobial Agents and Chemotherapy Jan 2006, 50 (2) 819-821; DOI: 10.1128/AAC.50.2.819-821.2006

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro Activity of Doripenem against Pseudomonas aeruginosa and Burkholderia cepacia Isolates from both Cystic Fibrosis and Non-Cystic Fibrosis Patients
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In Vitro Activity of Doripenem against Pseudomonas aeruginosa and Burkholderia cepacia Isolates from both Cystic Fibrosis and Non-Cystic Fibrosis Patients
M. M. Traczewski, S. D. Brown
Antimicrobial Agents and Chemotherapy Jan 2006, 50 (2) 819-821; DOI: 10.1128/AAC.50.2.819-821.2006
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
Burkholderia cepacia
carbapenems
cystic fibrosis
Pseudomonas aeruginosa

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596